1,720,987 research outputs found
Autologous stem cell transplantation: is it still relevant in breast cancer?
No full textThe journey to personalized breast cancer (BC) care, based on molecular tumor characteristics, is still long in the majority of patients as cytotoxic chemotherapy (CT) remains a pivotal therapeutic approach in
operable and advanced disease. The clinical correlation between dose-intensity of CT, that can be achieved by either increasing the single dose per cycle (i.e., higher dose) or by reducing the intervals between cycles
(i.e., dose density), and outcome in BC has been described since the eighties [1], leading to the premature acceptance of high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) as a
treatment option both in the adjuvant setting and for metastatic disease, with thousands of patients per year undergoing this procedure in the mid-1990s in Europe and North America [2]. Unfortunately, the vast
majority of patients were treated outside prospective randomized studies. At the turn of the century, in view of early
reports of randomized trials not showing a significant overall survival (OS) benefit of HDC in the adjuvant and metastatic settings [3], this procedure was no longer considered an option for the vast majority of medical oncologists. In the era of great expectations for targeted drugs, data from randomized studies demonstrating an OS
benefit by HDC for high-risk breast cancer (HRBC) [4,5], along with additional evidence of the benefit of intensified CT [6], did not change this attitude. This article is aimed to clarify what happened over the years in this controversial
field and whether today HDC with ASCT can be proposed in patients with BC
Reply to: Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO)
No full textHigh-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Support for Solid Tumors in Adults
No full textSupported by experimental evidence and convincing results of early phase II studies, since the 1980s high-dose chemotherapy (HDC) with autologous hematopoietic stem cell support (AHSCT) has been uncritically adopted by many oncologists as a potentially curative option for several solid tumors. As a result, the number (and size) of randomized trials comparing this approach with conventional chemotherapy initiated (and often abandoned before completion) in this setting was limited and the benefit of a greater escalation of dose of chemotherapy with stem cell transplantation in solid tumors remains, with the possible exception of breast carcinoma (BC) and germ cell tumors (GCT), largely unsettled. In this article, we review and comment on the data from studies to date of HDC for solid tumors in adults
Are metastatic testicular tumors curable with high-dose chemotherapy and stem-cell rescue?
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia
No full textUnresponsiveness to erythropoiesis-stimulatory agents (ESA), which occurs in 30% to 50% of patients, is a major limitation to the treatment of chemotherapy-related anemia (CRA). This may be related in part to the dysregulation of iron metabolism, leading to functional iron deficiency. However, the use of iron supplementation during treatment with ESA has not been pursued as rigorously in anemic patients with cancer as it has in patients with chronic kidney disease. In this article, the authors discuss the role of iron supplementation in the setting of CRA in view of recent reports that have addressed this issue
- …
